

**Detailed description of the subject of the order**

***Purchase financed from the state budget from the Medical Research Agency as part of the project:***

***Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety***

***Financing contract number: 2021/ABM/05/00004-00***

Technical specification:

- I. 4 antisense oligonucleotides (ASO) 300 nmol each have to be able to block polyadenylation sites. Hence, they need to operate via an RNase H-independent steric blocking mechanism. It is necessary that required ASOs are comprised of a nucleic acid base, a methylenemorpholine ring and a non-ionic phosphorodiamidate intersubunit linkage. Sequences of oligonucleotides that are the subject of the order:
  1. Custom Oligo 1 – GCGATTCACATACTTTACACGGGCA
  2. Custom Oligo 2 – CTGTCTCATGCAGCACAGGC
  3. Custom Oligo 3 - CTTTAATTTGGATGTACAATGTTTGCAGCA
  4. Custom Oligo 4 – GAAGCAAAGCAAGCCTCACACAGCA
  
- II. Control oligo (ASO), 300 nmol. It is necessary that required ASO is comprised of a nucleic acid base, a methylenemorpholine ring and a non-ionic phosphorodiamidate intersubunit linkage. It is essential for the control oligo to have a conjugated fluorescent tag on its 3' end.
  
- III. Chemical reagent which allows the delivery of ASOs into eukaryotic cells (volume: 1 ml).